Angiochem (Canada)
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB. Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential trea
Basic Information
- Category: business
- Website: http://angiochem.com/
Documented Facts
- Founded: 2003 (No linked source recorded for this statement.)
Evidence and Sources
- Angiochem (Canada) — Official Website (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Angiochem (Canada).
- Canonical profile: https://brandsource.ai/brands/angiochem-canada
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/angiochem-canada/json-ld
- Citation profile API: https://brandsource.ai/api/brands/angiochem-canada/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB. Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential trea
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.